Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Chief Strategy Officer | August 11, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date August 11, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,041 |
Reported balance
After 2026-08-11 transaction · row 1
1 source rowRow 1 · 2026-08-11 · Sale · Disposed 2,655 · Balance 37,041 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.54 to $19.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.54 to $19.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2026 Filed Aug 12, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 2,655 | $19.59 | $52,012.25 |
DisclosureSEC source: 0002047607-26-000008 · form4-08122026_040809.xml · nonDerivative · entry 1 Riley Jennifer · CIK 0002047607 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,041 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.54 to $19.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:43 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Tax withholdingCommon Stock | 588 | $13.10 | $7,702.80 |
DisclosureSEC source: 0002047607-26-000006 · form4-06122026_080614.xml · nonDerivative · entry 1 Riley Jennifer · CIK 0002047607 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,696 F1 · balance_after: Includes 3,429 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantCommon Stock | 34,200 | $0.00 | $0.00 |
DisclosureSEC source: 0002047607-26-000004 · form4-05262026_040508.xml · nonDerivative · entry 1 Riley Jennifer · CIK 0002047607 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,855 F1 · kind: Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:23 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $17.64 | $0.00 |
DisclosureSEC source: 0002047607-26-000002 · form4-03022026_090329.xml · derivative · entry 1 Riley Jennifer · CIK 0002047607 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2036-02-26 F1 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:18 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Tax withholdingCommon Stock | 637 | $4.10 | $2,611.70 |
DisclosureSEC source: 0001470831-25-000411 · form4.xml · nonDerivative · entry 1 Riley Jennifer · CIK 0002047607 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,655 F1 · balance_after: Includes 2,655 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:06 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $7.43 | $0.00 |
DisclosureSEC source: 0001578563-25-000002 · primary_doc.xml · derivative · entry 1 Riley Jennifer · CIK 0002047607 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: Twenty-five percent (25%) of the Option Shares vest on January 1, 2026 and the remainder of the Option Shares will vest in equal monthly installments over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.